


Back From Holiday

Do You Know Where **Your**
Patients Have Traveled?



Endemic countries for carbapenemase producing
Enterobacteriae (CPE) and vancomycin resistant enterococci (VRE)¹⁻⁵



Minimize Risk of Outbreaks: Screen Your Travelers

Following the KRINKO (Commission on Hospital Hygiene and Infection Prevention) recommendations, all patients admitted to the hospital and that had contact with healthcare system in countries with a known endemic situation for 4 MRGN (multiresistant Gram-negative) pathogens, have to be screened for the 4 MRGN.⁶

Importation of carbapenemases from specific areas in Europe as a consequence of cross-border transfer of patients, travel, medical tourism and refugees might play an important role in the transmission of carbapenemases.⁷

The VRE prevalence is changing in some European countries, and the risk to move from a sporadic to an endemic situation is real from repatriated people or foreign travelers requiring hospital care. Countries like France have issued national guidelines for controlling their spread, and advise to screen these patients.⁸

Cepheid Xpert® Tests:

Your fast and easy solution to screen those risk patients back from holiday

Xpert® Carba-R and Xpert® *vanA/vanB* tests for the GeneXpert® System can be an important & easy tool to identify those travellers carrying an unwanted souvenir and minimize the risk of outbreaks originating from travelers. These tests help to reduce preventable ward closures and avert outbreaks of highly resistant bacteria — such as vancomycin-resistant Enterococcus (VRE) and carbapenemase-producing Enterobacteriaceae (CPE) for patients who have been hospitalized abroad or have been in contact with CPE and VRE carriers.



Xpert® Carba-R

Detect “Big 5 Carbapenemase Gene Families” in 48 minutes

Xpert Carba-R is the only rapid test to detect and differentiate the most prevalent carbapenemases gene families (KPC, NDM, VIM, IMP-1, and OXA-48) in 48 minutes. This test helps healthcare providers to prevent widespread outbreaks and to guide infection prevention pathways. Xpert Carba-R supports active screening of patients transferred across borders and between healthcare facilities.^{9,10}



Xpert® *vanA/vanB*

Detect the Glycopeptide resistant enterococci in 47 minutes

Patients colonized with VRE have a high risk of infection and high mortality¹¹. Rapid identification of VRE carriers with Xpert *vanA/vanB* has been shown to support better patient and infection control management by helping to prevent the spread of VRE and minimizing VRE outbreaks^{12,13}

References:

1. Lee C-R et al. Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods. *Front. Microbiol.* Jun. 2016 /7:895
2. Logan L.K. et al The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. *J Infect Dis.* 2017 Feb 15;215(suppl_1):S28-36.
3. Mendes R. E. et al. Longitudinal (2001–14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010–13) analysis of oritavancin in vitro potency. *J Antimicrob Chemother* 2016; 71: 3453–3458.
4. Antimicrobial resistance surveillance in Europe 2015, available on: <http://www.ecdc.europa.eu>
5. https://www.cddep.org/tool/vancomycin_resistant_enterococci_rates_country
6. Hygienemaßnahmen bei Infektionen oder Besiedlung mit multiresistenten gramnegativen Stäbchen, KRINKO, Bundesgesundheitsbl 2012 · 55:1311–1354
7. Canton et al, *Clin Microbiol Infect* 2012; 18: 413–431
8. Lepelletier D, Andremont A, Grandbastien B et al. Risk of highly resistant bacteria importation from repatriates and travelers hospitalized in foreign countries: about the French recommendations to limit their spread. *J Travel Med* 2011; 18: 344–51.
9. Hoyos et al. *Int J Antimicrob Agents.* 2017 Jun;49(6):774-777
10. Moore et al, *J. Clin. Microbiol.* doi:10.1128/JCM.00137-17
11. Vydra J, et al. Enterococcal Bacteremia Is Associated With Increased Risk of Mortality in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. *Clin Infect Dis.*2012;55(6):764-70
12. Jauregui F, et al, Impact of the Cepheid Xpert vanA/vanB on the management of patients at risk of carrying glycopeptide-resistant enterococci. *ECCMID Amsterdam 2016.*
13. Birgand G, et al. Rapid detection of glycopeptide-resistant enterococci: impact on decision making and costs. *Ant Res Infect Cont.*



CORPORATE HEADQUARTERS

904 Caribbean Drive
Sunnyvale, CA 94089 USA

TOLL FREE +1.888.336.2743
PHONE +1.408.541.4191
FAX +1.408.541.4192

EUROPEAN HEADQUARTERS

Vira Soleih
81470 Maurens-Scopont France

PHONE +33.563.82.53.00
FAX +33.563.82.53.01
EMAIL cepheid@cepheideurope.fr

www.Cepheidinternational.com